The Ever-increasing Complexity of Biotech Changes - A Pledge for Global Convergence
|
|
- Patience Stevens
- 8 years ago
- Views:
Transcription
1 The Ever-increasing Complexity of Biotech Changes - A Pledge for Global Convergence CMC Strategy Forum, Sorrento, May 7th, 2014 Susanne Ausborn, Pharma Technical Regulatory Policy F. Hoffmann-La Roche, Basel, Switzerland
2 Presentation Outline Summarize complexity and current challenges of global life-cycle management Illustrate issues using typical examples Conclude with some reflections for pragmatic solutions to drive global convergence of post-approval change regulations 2
3 Many pharmaceutical companies manufacturing biotherapeutics are operating globally and have global manufacturing sites Global registration with Health Authorities Global supply chain Multiple sourcing strategy 3
4 Life Cycle Complexity and Challenges Complexity Some case studies Reflections on pragmatic solutions 4
5 The content differences at original submission are the first main cause for life-cycle complexity Approximately 192 recognized states Activities in ~140 countries Two categories of CMC packages ICH-like requirements in 20 countries Countries accepting less detailed information Trend towards introduction of country-specific or regional data Degree of detail Declarations Raw data Submission of GMP documents - paper inspections 5
6 Approved details differ from country to country after Q&A compared to the submitted dossier 100 Approval 20 Approval 6
7 One global submission can lead to multiple locally registered contents For Example: Each pin reflects a dossier with separate regulatory commitments for one product application..24 separate registrations for one product Adapted from: Colgan; ISPE annual meeting Nov
8 Introducing changes to the manufacturing process or the control system is an essential part of a products life-cycle Ensure market access and continuous supply of live-saving drugs to patients by reacting to supply demands Support continuous improvement and optimization of manufacturing process and quality of the medicinal products Remain state-of-the-art with manufacturing methods and analytical techniques Fulfill regulatory agency requirements 8
9 Approved details differ from country to country after Q&A compared to the submitted dossier 100 Approval Change 1 20 Approval 20 9
10 Post approval change requirements and need for sequential submission complicate further Change classifications different or not available Country-specific requirements (e.g., stability, raw data) Long/unpredictable approval timelines Backlog due to high review demand at Health Authorities CPP* needed for submission? Complex supply planning/ high bridging stocks Drug shortage Hinder innovation and continual improvement of process and product Quality and safety *CPP= Certificate of Pharmaceutical Product 10
11 Any change is a multiple year endeavor when it is executed on a global scale Data Doc Review 0-10 m CPP Wave 1: ICH dossier countries Doc Reviews 6-20 m Wave 2: Non-CPP Wave 3: CPP countries Review 6-24 m Time (elapsed months) 11
12 Life cycle complexity is resource intensive for authorities and industry Complexity Some case studies Reflections on pragmatic solutions 12
13 Case Study 1: an apparently minor change in an in-process analytical method Change description Modification of a Virus IPC test method of cell culture fluids 13
14 Case Study 1: Product A is registered in 127 countries at the time of the minor change 14
15 Case Study 1: The dispatch to all concerned countries was done mid May
16 Case Study 1: Actual submission occurred following dispatch between May and December 2011 Within 30 days Submission not required Not submitted Within 6 months 16
17 Case Study 1: The last approval took 20 months from submission and closure was after 26 months Within 30 days More than 12 months Submission not required Within 6 months Within 12 months 17
18 Case study 2: a technology transfer for a Drug product Change description Technology transfer of the Drug Product manufacturing process to an additional site 18
19 Case study 2 Product 2 is registered in 120 countries at the time of the Drug Product Site change 19
20 Case study 2: The change was dispatched to all but three countries in 2 waves Mar-Jun 2006 May Jul 2007 Not required 20
21 Case study 2 : The actual submission was performed within 10 months by the majority of countries Not recorded Less than 1 m More than 12 m 2 to 12 m Not required 21
22 Case study 2: The time from submission to approval where recorded varied substantially Not recorded 2-12 m Less than 1m Not required More than 12 m 22
23 Case study 2: A majority of countries approved in 24 months after dispatch but global implementation took 41 months Less than 12 m Less than 36 m More than 36 m Less than 24 m Not required 23
24 Life cycle complexity is resource intensive for authorities and industry A global change requires multiple years until complete implementation Reflections on pragmatic solutions 24
25 Harmonization of key principles will accelerate implementation of changes globally Change Classification concept Procedural guidance incl. timelines Documentation and data requirements... 25
26 WHO could coordinate convergence of regulation Change classification driven by potential to impact patient safety and efficacy. Risk based categorization Post-approval change management plans / comparability protocols Development of global classification and procedural guidance Drive progress: Fast track changes that improve quality Definition of documentation and data requirements for each change type Remove GMP elements 26
27 Driving global regulatory convergence Efforts under discussion - Expand the scope of WHO draft guideline for changes to a vaccine to biotherapeutic products and Biotherapeutic Products 27
28 Overview of the guideline (ToC) 1. ABBREVIATIONS 2. INTRODUCTION AND SCOPE 2.1 Introduction 2.2 Scope 3. GLOSSARY 4. GENERAL CONSIDERATIONS 5. REPORTING CATEGORIES FOR QUALITY CHANGES 5.1 Major Quality Changes 5.2 Moderate Quality Changes 5.3 Minor Quality Changes 6. REPORTING CATEGORIES FOR SAFETY, EFFICACY AND/OR PRODUCT LABELING INFORMATION CHANGES 6.1 Safety and Efficacy Changes 6.2 Product Labeling Information Changes 6.3 Administrative Product Labeling Information Changes 7. PROCEDURES 7.1 Procedures for Prior Approval Supplement 7.2 Procedures for Minor Quality Changes 7.3 Procedures for Administrative Product Labeling Information Changes 7.4 Accelerated Procedures for Urgent Changes 8. SPECIAL CONSIDERATIONS 8.1 Adjuvants 8.2 Influenza Vaccines 8.3 Bridging Studies 9. REFERENCES APPENDIX 1 - Reporting categories and suggested review time lines APPENDIX 2 - Post approval changes to the antigen APPENDIX 3 - Post approval changes to the final product APPENDIX 4 - Safety, efficacy and product labeling information post approval changes 28
29 Extract from WHO draft guideline for vaccines 2 INTRODUCTION AND SCOPE This document provides guidelines for NRAs and MA holders who intend to make changes to the original MA or product license for an approved vaccine on: a) procedures and criteria for the appropriate categorization and reporting of changes; and b) the data required to enable NRAs to evaluate the impact of the change on the quality, safety and efficacy of the vaccine. Additionally, the purpose of this guidance is to assist NRAs in establishing procedures for post approval changes of vaccines. This guidance applies to the manufacture and use of approved prophylactic vaccines for humans. However, general principles of this document may apply to other biological products. Proposal to expand the scope of the guideline to Biotherapeutic products prepared by rdna technology 29
30 Extract from WHO draft guideline for vaccines 5. REPORTING CATEGORIES FOR QUALITY CHANGES Based on the potential effect of the quality change (e.g., manufacturing change) on the quality attributes (i.e., identity, strength, quality controls, purity, potency) of the vaccine and on their potential impact on the quality, safety or efficacy of the vaccine, changes are categorized into major, moderate and minor and are identified as: - Major Quality Changes, - Moderate Quality Changes, or - Minor Quality Changes. Quality changes listed in Appendices 2 and 3 should be reported in one of the reporting categories described in this section. If a quality change may have a potential impact on the quality, safety and efficacy of the vaccine and is considered to be major, moderate or minor, but is not included in Appendix 2 or 3, then the NRA should be consulted for proper classification. Classification concept is applying risk-based approach 30
31 Extract from WHO draft guideline for vaccines Category Supplement Maximum Review Time Quality Changes Major Quality Changes Significant potential to have negative impact on Q;S;E Prior Approval Supplement 6 months Moderate Quality Changes Minor Quality Changes Moderate Potential to have negative impact on Q;S;E Prior Approval Supplement Moderate Potential to have negative impact on Q;S;E Do not require notification to the NRA 1 3 months N/A clear procedural guidance and review timelines are proposed 31
32 Extract from WHO draft guideline for vaccines detailed dossier requirements are provided Key elements for biotherapeutics have to be included: Describe relevant changes Identify the conditions Define supporting data for given change, eg batch analysis data, stability standards (eg. accelerated stability studies + NMT 6 months real time data to maintain shelf-life...) 32
33 Global guidance established by WHO could drive convergence Global LIFE-CYCLE Management will be a topic at the APEC biotherapeutic workshop (parallel to WHO meeting in May 2014, Korea) 33
34 Life cycle complexity is resource intensive for authorities and industry A global change requires multiple years until complete implementation Convergence of requirements and mutual recognition can reduce the complexity of life cycle changes, efforts are on the way 34
35 Global convergence of post-approval change regulations offers a «Win-Win» outcome for regulators, industry & patients Harmonized post-approval regulations Change classification, procedures, dossier requirements Regulators Industry Patients -Prioritize based on criticality of change -Facilitate assessment of changes -Enhance collaboration/ knowledge sharing with other agencies -Allow better planning and execution of changes -No additional country-specific data to be created -Reduce complexity in supply chain -Improved drug quality rapidly accessible to the market - High quality standard maintained globally Reliable supply of high quality drugs to all patients GLOBALLY Mutual recognition of regulatory decisions Transparency 35
36 Acknowledgements Ralf Gleixner, Wassim Nashabeh, Thomas Schreitmueller & Kowid Ho- Roche / Genentech Richard Lit - Amgen, Inc. 36
37 Doing now what patients need next
Risk-Based Change Management Using QbD Principles
Risk-Based Change Management Using QbD Principles Lynne Krummen, Ph.D. VP, Global Head, Technical Regulatory Biologics Genentech, a member of the Roche Group CMC Forum 2013 Tokyo, Japan Presentation Outline
More informationTaking a Leap Toward Global Supply Chain Efficiency
Taking a Leap Toward Global Supply Chain Efficiency 2 Taking a Leap Toward Global Supply Chain Efficiency INTRODUCTION PROBLEM STATEMENT Pharmaceutical manufacturers face a number of challenges to produce
More informationLifecycle CMC Management: ICH Q12 Progress to date
Lifecycle CMC Management: ICH Q12 Progress to date BWP/QWP/GMDP IWG Industry European workshop 28-29 October 2015 Jean-Louis ROBERT (EU) Graham Cook (EFPIA) Please take note The following slides represent
More informationNRA FUNCTION IN CONTROLLING VACCINES IN CLINICAL TRIAL AND MARKETING AUTHORIZATION INDONESIA 2013 DVI MEETING 9 11 APRIL 2013 1
NRA FUNCTION IN CONTROLLING VACCINES IN CLINICAL TRIAL AND MARKETING AUTHORIZATION INDONESIA 2013 DVI MEETING 9 11 APRIL 2013 1 2 The National Agency of Drug and Food Control (NA-DFC) is a non departmental
More informationICH Q 10 Pharmaceutical Quality System PQS DIA China Annual Meeting, May 2010
ICH Q 10 Pharmaceutical Quality System PQS DIA China Annual Meeting, May 2010 Joseph C. Famulare Head of External Relations and Collaboration Pharma Global Technical Operations Global Quality, F. Hoffmann-La
More informationAn FDA Perspective on Post- Approval Change Management for PAT and RTRT
An FDA Perspective on Post- Approval Change Management for PAT and RTRT IFPAC 2015 January 26, 2015 Christine M. V. Moore, Ph.D. Acting Director, Process and Facilities FDA/CDER/OPQ Post-Approval Changes
More informationGUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs.
15 January 2007 GUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs.) TABLE OF CONTENTS 1 INTRODUCTION... 2 2
More informationIndustry Implications of Pharmaceutical Quality ICH Guidelines
EIPG General Assembly Industry Implications of Pharmaceutical Quality ICH Guidelines 20 th April 2008 Pharmaceutical Quality Develop a harmonised pharmaceutical quality system applicable across the lifecycle
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP)
European Medicines Agency Veterinary Medicines and Inspections London, 15 April 2005 EMEA/CVMP/134/02 Rev 1 CPMP/QWP/227/02 Rev 1 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY
More informationGuide to Fees for Veterinary Products
Guide to Fees for Veterinary Products FIN-G0003-14 04 FEBRUARY 2016 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS ABBREVIATIONS
More informationExpectations for Data to Support Clinical Trial Drugs
Expectations for Data to Support Clinical Trial Drugs Presentation to: APEC Advanced Workshop on Review of Drug Development in Clinical Trials Bangkok Thailand Feb 2-6 2009 Willem Stevens Ph.D., Chief
More informationWorking with ICH Quality Guidelines - the Canadian Perspective
Working with ICH Quality Guidelines the Canadian Perspective Krishnan Tirunellai, Ph. D. Bureau of Pharmaceutical Sciences Therapeutic Products Directorate Health Canada December 3, 2008 Outline Introduction
More informationPharmaceutical Quality Management System: Current Concept
Pharmaceutical Quality Management System: Current Concept Neetu Dubey 1, *, Himanshu Gupta 3, R.K. Sharma 2, Nitin Dubey 1, Nidhi Dubey 4 1. IPS Academy, Indore, Madhya Pradesh, India. 2. Prestige Institute
More informationGuidance for Industry. Q10 Pharmaceutical Quality System
Guidance for Industry Q10 Pharmaceutical Quality System U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation
More informationFebruary 2006 Procedural
Guidance for Industry Reports on the Status of Postmarketing Study Commitments Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997 U.S. Department of Health and
More informationChanges to an Approved Product
Changes to an Approved Product Chemistry, Manufacturing and Controls By Khandan Baradaran, PhD and Peggy Berry, MBA, RAC It is a huge achievement for any company to obtain licensing rights to an approved
More informationLibrary Guide: Pharmaceutical GMPs
Library Guide: Pharmaceutical GMPs Table of Contents Overview...3 Courses Listed by Functional Area... 4 Course Descriptions: A Step-by-Step Approach to Process Validation (PHDV79)... 7 A Tour of the FDA
More informationManufacturing process of biologics
Manufacturing process of biologics K. Ho Afssaps, France 2011 ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 2011 ICH 1 Disclaimer:
More informationEXPERT REVIEW PANEL PROCEDURE: ADDITIONAL SUPPORT TO PROCUREMENT AGENCIES UNDER EXCEPTIONAL CIRCUMSTANCES
EXPERT REVIEW PANEL PROCEDURE: ADDITIONAL SUPPORT TO PROCUREMENT AGENCIES UNDER EXCEPTIONAL CIRCUMSTANCES Introduction The WHO Prequalification of Medicines Programme (PQP) was established to provide UN
More informationGLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group dpifat@bcg-usa.com
GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group dpifat@bcg-usa.com Common Misconception Good Laboratory Practices 1) A quality system concerned with the organizational process
More informationComparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE
Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Dr. Fulvio CARLOTTI, GNOSIS SpA, Corporate QA Director September 26, 2014 Scope of GMP GMP compliance
More informationTRANSATLANTIC TRADE AND INVESTMENT PARTNERSHIP
DISCLAIMER: The EU reserves the right to make subsequent modifications to this text and to complement its proposals at a later stage, by modifying, supplementing or withdrawing all, or any part, at any
More informationThe FDA recently announced a significant
This article illustrates the risk analysis guidance discussed in GAMP 4. 5 By applying GAMP s risk analysis method to three generic classes of software systems, this article acts as both an introduction
More informationWorkshop B Control Strategy
ICH-GCG ASEAN Workshop B Control Strategy Jean-Louis ROBERT, Ph.D. National Health Laboratory, Luxembourg Chair-person ICH IWG Q8, Q9, Q10 Kuala Lumpur, 26-28 July 2010 International Conference on Harmonisation
More informationWorkshop on process validation
Workshop on process validation General concepts on process validation Kowid Ho Scope / background Process evaluation/validation of biotechnology derived proteins used as active substance in the manufacture
More informationA Stability Program for the Distribution of Drug Products
A Stability Program for the Distribution of Drug Products Teresa I. Lucas*, Rafik H. Bishara, and Robert H. Seevers Drug products must be transported in a manner that ensures products will be maintained
More informationGMP/Regulatory Environment in the
GMP/Regulatory Environment in the Latin America Irene Ortiz Barreal, Pharm. D., R.Ph. Pfizer International Affiliate Quality Compliance Regional Leader Latin America/Caribbean April 14, 2011 Discloser
More informationPHARMACEUTICAL QUALITY SYSTEM Q10
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE PHARMACEUTICAL QUALITY SYSTEM Q10 Current Step
More informationQuestions and answers on post approval change management protocols
30 March 2012 EMA/CHMP/CVMP/QWP/586330/2010 Committee for Medicinal Products for Human Use (CHMP) Questions and answers on post approval change management protocols Draft agreed by CHMP / CVMP Quality
More informationTechnology Transfer of CMC Activities for MAb Manufacturing. 2010 ge healthcare (www.gelifesciences.com)
M a n u f a c t u r i n g OPERATIONS Technology Transfer of CMC Activities for MAb Manufacturing by Patricia Seymour, Susan Dana Jones, Howard L. Levine With combined 2009 revenues estimated to be over
More informationQuality Considerations for Breakthrough Therapies-FDA Perspective
Quality Considerations for Breakthrough Therapies-FDA Perspective DIA June 17, 2014 Ramesh K. Sood, Ph.D. Acting Division Director and Angelica Dorantes, Ph.D. xxx ONDQA/OPS/CDER/FDA 1 Background Outline
More informationQuality by Design Application and Perspectives for biologicals. K. Ho, CHMP Biologics Working Party
Quality by Design Application and Perspectives for biologicals K. Ho, CHMP Biologics Working Party Pharmaceutical development (Q8) Aim: To design a quality product and a manufacturing process to consistently
More informationWhat to control? CQAs and CPPs
What to control? CQAs and CPPs Dr. Thomas Stangler On behalf of the European Generic medicines Association Development Strategy & Technology Manager Sandoz Biopharmaceuticals 1 Martin Schiestl Singapore,
More informationGuidance for Industry
Guidance for Industry Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products For questions on the content of the guidance,
More informationGuidance for Industry
Guidance for Industry Q8, Q9, and Q10 Questions and Answers(R4) U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics
More information[NAME OF NATIONAL REGULATORY AUTHORITY] PROCEDURE FOR SUBMISSION CLINICAL TRIAL APPLICATIONS VACCINES AND BIOLOGICALS [COUNTRY]
[TEMPLATE] [NAME OF NATIONAL REGULATORY AUTHORITY] PROCEDURE FOR SUBMISSION OF CLINICAL TRIAL APPLICATIONS OF VACCINES AND BIOLOGICALS IN [COUNTRY] 1of 19 General Procedures for clinical trial applications
More informationAnnex 2 Stability testing of active pharmaceutical ingredients and finished pharmaceutical products
World Health Organization WHO Technical Report Series, No. 953, 2009 Annex 2 Stability testing of active pharmaceutical ingredients and finished pharmaceutical products 1. Introduction 1.1 Objectives of
More informationPost-Approval Change Management: Challenges and Opportunities An FDA Perspective
CMC Workshop From Drug Development to Global Supply to Patients April 15-17, 2013, Washington, DC Post-Approval Change Management: Challenges and Opportunities An FDA Perspective Christine M. V. Moore,
More informationICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/ biological entities)
November 2012 EMA/CHMP/ICH/425213/2011 ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/ biological entities) Step 5 Transmission to CHMP May
More informationGuideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)
22 May 2014 EMA/CHMP/BWP/247713/2012 Committee for Medicinal Products for Human Use (CHMP) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance:
More informationUnedited version adopted by the 45th WHO Expert Committee on specifications for pharmaceutical preparations. World Health Organization 2010
GUIDELINE ON SUBMISSION OF DOCUMENTATION FOR A MULTISOURCE (GENERIC) FINISHED PHARMACEUTICAL PRODUCT (FPP): PREPARATION OF PRODUCT DOSSIERS (PDS) IN COMMON TECHNICAL DOCUMENT (CTD) FORMAT Unedited version
More informationICH Public Meeting. Joseph C. Famulare. October 2, 2006. Acting Deputy Director Office of Compliance CDER / FDA Office of Compliance
ICH Public Meeting October 2, 2006 Joseph C. Famulare Acting Deputy Director Office of Compliance CDER / FDA Office of Compliance The Current State of Pharmaceutical Manufacturing Inability to predict
More informationConducting a Gap Analysis on your Change Control System. Presented By Miguel Montalvo, President, Expert Validation Consulting, Inc.
Conducting a Gap Analysis on your Change Control System Presented By Miguel Montalvo, President, Expert Validation Consulting, Inc. Standards, Regulations, Guidelines related to Change Control Management
More informationAnnex 6. Guidance on variations to a prequalified product dossier. Preface
Annex 6 Guidance on variations to a prequalified product dossier Preface This guidance document was technically and structurally inspired by the Guideline on dossier requirements for type IA and IB notifi
More informationPHARMACEUTICAL DEVELOPMENT
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE PHARMACEUTICAL DEVELOPMENT Q8(R2) Current Step
More informationHOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) GUIDANCE ON MODULE 3 OF THE HOMEOPATHIC MEDICINAL PRODUCTS DOSSIER
HOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) GUIDANCE ON MODULE 3 OF THE HOMEOPATHIC MEDICINAL PRODUCTS DOSSIER DISCUSSION IN THE HMPWG 2003-2005 RELEASE FOR CONSULTATION December 2005 DEADLINE
More informationPreparing for the Pre-Approval Inspection What to do Before the FDA Arrives. Barry A. Friedman, Ph.D. Consultant
Preparing for the Pre-Approval Inspection What to do Before the FDA Arrives Barry A. Friedman, Ph.D. Consultant FDA Overview FDA is a consumer protection agency within the Department of Health & Human
More informationSession 6: WHO Prequalification Programme. Key Process Steps WHO: Medicines UNFPA: Condoms and IUDs
Session 6: WHO Prequalification Programme Key Process Steps WHO: Medicines UNFPA: Condoms and IUDs Session adapted from the WHO training workshop on prequalification and the WHO technical briefing seminar
More informationGuide to Master Formulae WHO/FWC/IVB/QSS/VQR
WHO/FWC/IVB/QSS/VQR 2011 This guidance document GUIDE TO MASTER FORMULAE is one of a series developed by WHO/FWC/IVB Quality, Safety & Standards team upon request from the manufacturers members of the
More informationPROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013)
January 2013 RESTRICTED PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013) DRAFT FOR COMMENTS Please address any comments on this proposal
More informationHarmonizing Change Control Processes Globally
Quality & Compliance Associates, LLC Harmonizing Change Control Processes Globally President Quality & Compliance Associates, LLC When We Deal In A Global Environment, How Do We Design A System That Addresses
More informationClinical Trial Data Transparency Environment & Expectations EMA Policy - Clinical Trials Regulation
Clinical Trial Data Transparency Environment & Expectations EMA Policy - Clinical Trials Regulation Joint BBS-EFSPI Seminar, Basel, 13 Nov 2014 Sabine Atzor, Head of EU Regulatory Policies PDR Overview
More informationGood Manufacturing Practices: A Synopsis of Their Role and Rationale in Today's Pharmaceutical Marketplace for Tubing
Good Manufacturing Practices: A Synopsis of Their Role and Rationale in Today's Pharmaceutical Marketplace for Tubing Katherine L. Ulman and Dr. Patricia Rafidison Dow Corning Healthcare About the Authors
More informationNEW CHEMICAL ENTITIES
NEW CHEMICAL ENTITIES PIONEERING PARTNER FOR PEPTIDES With more than 40 years of expertise in peptide synthesis, a track record in process development, large-scale manufacturing and outstanding product
More informationHSA Consumer Guide. Understanding Vaccines, Vaccine Development and Production. www.hsa.gov.sg November 2009. How a Vaccine Works.
November 2009 Understanding Vaccines, Vaccine Development and Production Vaccines, in general, help protect people from harmful infections before they come in contact with the disease. Vaccines may also
More informationGlobal regulatory affairs role in the biopharmaceutical industry
CHAPTER TWO Global affairs role in the biopharmaceutical industry 2.1 Overview 2.2 Global affairs organization 2.3 Role of global affairs 2.4 Key functions and activities 2.5 Global strategy 2.6 Global
More informationQuality Agreement. by and between. Supplier Name. Address: and. Client Name: Address:
NOTE TO USERS This Quality Agreement template was developed by the Bulk Pharmaceutical Task Force (BPTF), an affiliate organization of the Society of Chemical Manufacturers and Affiliates (SOCMA), as a
More informationICH guideline Q8, Q9 and Q10 - questions and answers volume 4
December 2010 EMA/CHMP/ICH/265145/ Committee for medicinal products for human use (CHMP) ICH guideline Q8, Q9 and Q10 - questions and answers volume 4 Step 5 Transmission to CHMP for information December
More informationImplementing Lifecycle Validation Practices at Contract Manufacturing Organizations
Implementing Lifecycle Validation Practices at Contract Manufacturing Organizations This paper discusses the nuances of lifecycle validation implementation at contract manufacturing organizations (CMOs).
More informationThe AVAREF joint review process of Ebola clinical trial applications
The AVAREF joint review process of Ebola clinical trial applications Dr Matthias Stahl, Regulation, Ebola R&D Team 1 Background WHO convened the 9 th annual meeting of the African Vaccine Regulatory Forum
More informationPharmaceutical Quality Systems: US Perspective
Pharmaceutical Quality Systems: US Perspective Rick Friedman Associate Director, Office of Manufacturing and Product Quality Center for Drug Evaluation and Research Topics Background: The ICH Q10 Pharmaceutical
More informationImporting pharmaceutical products to China
Importing pharmaceutical products to China Imported pharmaceutical products need pre-market approval before entering the Chinese market Imported drugs for human use are required to obtain pre-market approval
More informationPHARMACEUTICAL REFERENCE STANDARDS
PHARMACEUTICAL REFERENCE STANDARDS 11 th International Symposium organised by the European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe 3-4 September 2012, Strasbourg,
More informationQuality Assurance. Disclosure for Lilli Møller Andersen. No relevant financial relationships exist for any issue mentioned in this presentation
Quality Assurance Disclosure for Lilli Møller Andersen No relevant financial relationships exist for any issue mentioned in this presentation Agenda Quality Assurance Quality Management System Quality
More informationICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients questions and answers
23 July 2015 EMA/CHMP/ICH/468930/2015 Committee of Human Medicinal Products ICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients questions and answers Step 5 Transmission
More informationPROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7: NON-STERILE PROCESS VALIDATION
April 2013 RESTRICTED 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES:
More informationBest Practices In Ensuring Quality Standards When Outsourcing To Contract Manufacturers, Licensees And Consultants
Best Practices In Ensuring Quality Standards When Outsourcing To Contract Manufacturers, Licensees And Consultants Alex D. Kanarek, PhD BioProcess Technology Consultants, Inc. Strategic Institute Quality
More informationICH Q10 Pharmaceutical Quality System (PQS)
ICH Q10 Pharmaceutical Quality System (PQS) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Q10 PQS Guideline Background Objectives
More informationIntroduction to Q10 Pharmaceutical Quality System
ICH-GCG Asean Training Workshop on ICH Guidelines Q8,Q9 and Q10 (New Paradigm) Introduction to Q10 Pharmaceutical Quality System Georges FRANCE, Q- IWG Kuala Lumpur, Malaysia 26-28 July 2010 International
More informationRegulatory Affairs Graduate & Postgraduate Program. Novartis Pharma AG Novartis Animal Health AG
Regulatory Affairs Graduate Postgraduate Program Novartis Pharma AG Novartis Animal Health AG The Regulatory Affairs (RA) Graduate Program is an opportunity to discover the global functions of Drug Regulatory
More informationTransatlantic Trade and Investment Partnership (TTIP): Towards better health outcomes for patients and economic growth
Transatlantic Trade and Investment Partnership (TTIP): Towards better health outcomes for patients and economic growth 1 About EFPIA Þ EFPIA is the voice of the European innovative pharmaceutical industry,
More informationRegulation and Risk Management of Combination Products
Regulation and Risk Management of Combination Products Katherine Ulman Associate Scientist Global Regulatory Compliance Manager Dow Corning Healthcare Jim Curtis Senior Specialist, Healthcare Applications
More informationBiotech Concerto #3. European Clinical Trial Environment
Biotech Concerto #3 European Clinical Trial Environment December 2008 Index EU Directive EU Approval System European Authority: EMEA The Guidance Documents Route Map Challenges EMEA Organization Chart
More informationSTABILITY TESTING OF ACTIVE SUBSTANCES AND PHARMACEUTICAL PRODUCTS
RESTRICTED STABILITY TESTING OF ACTIVE SUBSTANCES AND PHARMACEUTICAL PRODUCTS Discussions are currently ongoing with the WHO Eastern Mediterranean Region towards a synergistic approach in developing a
More informationectd Digital Handbook Table of Contents
ectd Digital Handbook Table of Contents Introduction by Emily Ethridge, Editor, FDAnews Part 1 Tutorial Section 1.0 ectd Tutorial Table of Contents. This FDA tutorial, consisting of seven PowerPoint presentations,
More informationDeviation Handling and Quality Risk Management
Deviation Handling and Quality Risk Management A note for guidance for the manufacture of prequalified vaccines for supply to United Nations agencies July, 2013 Vaccine Quality and Regulations (VQR), Essential
More informationGuidance for Industry Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products
Guidance for Industry Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products U.S. Department of Health and Human Services Food and Drug Administration
More informationFrom Research Services and Process Development to GMP Manufacturing
From Research Services and Process Development to GMP Manufacturing P a r ag o n B i o s e r v i c e s, I n c. A contract research and GMP manufacturing organization (CMO) with a focus on the development
More informationBrazil s Model for SLDs Quality Assurance and Management: A Country Perspective. Joel Keravec MSH/SIAPS Brazil Country Director
Brazil s Model for SLDs Quality Assurance and Management: A Country Perspective Joel Keravec MSH/SIAPS Brazil Country Director IOM Workshop Washington DC - July 2012 Brazil TB/DR-TB Context Size : 8,547,403
More informationThe Clinical Trials Directive in the EU: Present and Future Elisabethann Wright, Partner Maurits Lugard, Partner. May 2010
The Clinical Trials Directive in the EU: Present and Future Elisabethann Wright, Partner Maurits Lugard, Partner May 2010 Background (1) The Clinical Trials Directive 2001/20/EC The intention of this Directive
More informationVolume 2B Notice to Applicants. Medicinal products for human use. Presentation and format of the dossier. Common Technical Document (CTD)
Volume 2B Notice to Applicants Medicinal products for human use Presentation and format of the dossier Common Technical Document (CTD) Introduction Edition June 26 Module 1 Edition May 28 Module 2 Edition
More informationAnnex 2. WHO guidelines on quality risk management. 1. Introduction 62. 2. Glossary 67 3. Quality risk management process 70
Annex 2 WHO guidelines on quality risk management 1. Introduction 62 1.1 Background and scope 62 1.2 Principles of quality risk management 64 2. Glossary 67 3. Quality risk management process 70 3.1 Initiating
More informationEU Clinical Trials Regulation Regulation EU 536/2014
EU Clinical Trials Regulation Regulation EU 536/2014 María Jesús Zafra Director, QA & Compliance Table of contents 1 2 3 4 Introduction Timelines and main changes Highlights 5 Impact on company processes
More informationICH guideline Q10 on pharmaceutical quality system
September 2015 EMA/CHMP/ICH/214732/2007 Committee for Human Medicinal Products Step 5 Transmission to CHMP May 2007 Transmission to interested parties May 2007 Deadline for comments November 2007 Final
More informationPOST-MASTER S CERTIFICATES in ADVANCED QUALITY ASSURANCE or REGULATORY AFFAIRS
Temple University - School of Pharmacy 425 Commerce Drive, Suite 175 Fort Washington, PA 19034 Phone: 267.468.8560 Fax: 267.468.8565 POST-MASTER S CERTIFICATES in ADVANCED QUALITY ASSURANCE or REGULATORY
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products- authorisations, European Medicines Agency Brussels, EudraLex The Rules Governing Medicinal
More informationWorkshop A Design Space (DS)
Implementation of ICH Q8, Q9, Q10 Workshop A Design Space (DS) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Disclaimer The information
More informationLICENCE FEES FOR MEDICINAL PRODUCTS FOR HUMAN USE ONLY PROPOSALS FOR APRIL 2002
Fax: 020 7273 0121 To all licence holders and representative associations Dear Sir/Madam Our Ref: MLX/277 15 November 2001 LICENCE FEES FOR MEDICINAL PRODUCTS FOR HUMAN USE ONLY PROPOSALS FOR APRIL 2002
More informationAddressing Risk in Partner / Contractor Selection and Onboarding. Michael Davidson VP Quality Systems and Compliance March 2014
Addressing Risk in Partner / Contractor Selection and Onboarding Michael Davidson VP Quality Systems and Compliance March 2014 Industry Trends Pfizer Overview Pfizer s Approach Risk Based Robust Due Diligence
More informationSPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT
SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT Guideline Title Specifications and Control Tests on the Finished Product Legislative basis Directive 75/318/EEC as amended Date of first adoption
More informationCombination Products Regulation in the United States
Combination Products Regulation in the United States Presenter: Scott Sardeson RAC US/EU 3M Health Care St. Paul, MN USA 1 Presentation Outline Combination products Definitions and Regulations Jurisdiction
More informationASSESSMENT OF QUALITY RISK MANAGEMENT IMPLEMENTATION
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 038-1 26 March 2012 AIDE-MEMOIRE ASSESSMENT OF QUALITY RISK MANAGEMENT IMPLEMENTATION PIC/S March 2012 Reproduction
More informationQUALITY BY DESIGN (QBD) : A COMPLETE REVIEW
Review Article QUALITY BY DESIGN (QBD) : A COMPLETE REVIEW Nishendu P. Nadpara*, Rakshit V. Thumar, Vidhi N. Kalola, Parula B. Patel Department of Quality Assurance, S. J. Thakkar Pharmacy College, Opp.
More informationOverview of WHO revised vaccine prequalification procedure
Overview of WHO revised vaccine prequalification procedure Carmen Rodriguez WHO/IVB/QSS Vaccine Industry Consultation meeting 25-26 January 2012 UNICEF SD Copenhagen Purpose of WHO vaccines prequalification
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE THE COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION
More informationSpeeding up access to markets: WHO Expert Review Panel & WHO accelerated registration procedure How manufacturers, procurers and patients benefit
Speeding up access to markets: WHO Expert Review Panel & WHO accelerated registration procedure How manufacturers, procurers and patients benefit JOINT UNICEF, UNFPA & WHO MEETING WITH MANUFACTURERS AND
More informationThe New EU Clinical Trials Regulation: The Good, the Bad, the Ugly
A Full-Service International CRO The New EU Clinical Trials Regulation: The Good, the Bad, the Ugly Dr. Martine Dehlinger-Kremer Vice President, Global Medical and Regulatory Affairs The original intent
More informationICH Topic Q 5 E Comparability of Biotechnological/Biological Products
European Medicines Agency June 2005 CPMP/ICH/5721/03 ICH Topic Q 5 E Comparability of Biotechnological/Biological Products Step 5 NOTE FOR GUIDANCE ON BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS SUBJECT TO CHANGES
More informationRAPS ONLINE UNIVERSITY
RAPS ONLINE UNIVERSITY Practical education and training for business success. For regulatory professionals, there is only one name to know and trust for online education and training RAPS Online University.
More informationOECD Recommendation on the Governance of Clinical Trials
OECD Recommendation on the Governance of Clinical Trials Marketing authorisation status of the medicinal products Non-authorised medicine Authorised medicine, treatment regimen outside
More information